WEBVTT 00:00:00.299 --> 00:00:02.901 A patient says she is taking a G L P 1 medicine 00:00:02.987 --> 00:00:05.909 and wants to become pregnant. Before you give her a stopping date, 00:00:06.016 --> 00:00:07.019 what do you need to know? 00:00:07.296 --> 00:00:09.536 Welcome to HEART RESERVE Clinical Conversations. 00:00:09.813 --> 00:00:13.973 I’m Lisa Zahakos, a physician assistant and founder of HEART RESERVE. 00:00:14.037 --> 00:00:18.304 In this episode, we’ll follow Maya as she plans conception, Leah as 00:00:18.347 --> 00:00:22.599 her treatment dose changes, and Nora after an unexpected pregnancy exposure. 00:00:22.884 --> 00:00:25.209 These are fictional teaching cases for clinicians. 00:00:25.444 --> 00:00:28.260 You can listen straight through, or use the chapters to return to 00:00:28.302 --> 00:00:31.161 a case. I’ll ask you to consider a few decisions and then 00:00:31.247 --> 00:00:35.628 walk through the reasoning. The activity page has the objectives, references and 00:00:35.671 --> 00:00:38.886 online questions. Let’s work through the first case. 00:00:39.270 --> 00:00:43.471 Maya takes injectable semaglutide for weight management and hopes to conceive soon. 00:00:43.661 --> 00:00:47.543 The conversation begins with her exact medicine and goals, the clinicians who 00:00:47.586 --> 00:00:50.402 need to be involved, and the care that must continue through the 00:00:50.445 --> 00:00:55.463 transition. Which product details and reproductive plans must you clarify before offering 00:00:55.548 --> 00:00:58.087 a timing rule? Let’s work through that question. 00:00:58.449 --> 00:01:04.508 Start with the exact medicine, formulation, dose, indication, last dose and reproductive 00:01:04.807 --> 00:01:10.621 situation. Is the patient planning conception, seeking contraception, newly pregnant or breastfeeding? 00:01:10.920 --> 00:01:15.613 Does she have type 2 diabetes, obesity without diabetes, cardiovascular disease or 00:01:15.698 --> 00:01:20.530 another relevant indication? These details prevent a general statement about "G L 00:01:20.530 --> 00:01:23.592 P 1s" from becoming an inaccurate instruction. 00:01:24.040 --> 00:01:28.997 Maya is a fictional 36-year-old taking injectable semaglutide solely for weight management. 00:01:29.262 --> 00:01:32.782 She has no established diabetes and hopes to conceive next month. 00:01:33.145 --> 00:01:37.112 Current Wegovy labeling calls for discontinuation at least two months before planned 00:01:37.155 --> 00:01:41.787 pregnancy. Her proposed timeline therefore needs discussion now, together with the prescriber 00:01:41.915 --> 00:01:46.523 and obstetric clinician. Agree on the last dose, the intended conception timeline 00:01:46.651 --> 00:01:51.493 and the interim health plan. Review current glucose status, nutrition, other medicines 00:01:51.664 --> 00:01:54.992 and the patient's priorities. The task is not simply to circle a 00:01:55.034 --> 00:01:58.277 date. It is to arrange the care that continues while treatment is 00:01:58.320 --> 00:02:03.801 stopped. Explain that the planning conversation should happen before contraception is discontinued. 00:02:04.182 --> 00:02:09.302 The current semaglutide label distinguishes some pregnancy advice by indication; this curriculum's 00:02:09.345 --> 00:02:14.208 cases concern weight management or diabetes-related transitions, not treatment of MASH with 00:02:14.251 --> 00:02:18.501 advanced fibrosis. Do not turn one case into a universal rule covering 00:02:18.586 --> 00:02:23.066 every indication. Confirm the current prescribing information before release and at the 00:02:23.109 --> 00:02:27.574 point of care. Coordinate the diabetes variation Priya is a fictional 35-year-old 00:02:27.660 --> 00:02:31.415 with type 2 diabetes, hypertension and obesity who wants to conceive. 00:02:31.756 --> 00:02:33.847 She has stopped her G L P 1 medicine on her own 00:02:34.017 --> 00:02:38.352 but has no replacement plan. She reports rising home glucose values. 00:02:38.736 --> 00:02:42.149 The medication has been stopped, but the clinical problem has not been 00:02:42.235 --> 00:02:47.983 resolved. The Endocrine Society and European Society of Endocrinology advise discontinuation before 00:02:48.196 --> 00:02:52.932 conception in people with type 2 diabetes, with individualized timing and active 00:02:53.145 --> 00:02:57.903 glycemic management. A timely transition to appropriate therapy is needed because deterioration 00:02:58.031 --> 00:03:01.509 in glucose control is itself important for pregnancy outcomes. 00:03:01.871 --> 00:03:05.412 Arrange prompt review rather than waiting for a routine follow-up several months 00:03:05.626 --> 00:03:11.360 away. A full preconception review includes other prescribed and nonprescribed medicines, blood 00:03:11.403 --> 00:03:15.259 pressure treatment, renal status and cardiovascular disease when relevant. 00:03:15.573 --> 00:03:19.242 The maternal-fetal medicine and endocrine teams should agree who manages each part 00:03:19.285 --> 00:03:24.020 of the transition. The preventive cardiologist contributes when established disease or a 00:03:24.063 --> 00:03:26.783 complex cardiovascular regimen changes the decision. 00:03:27.071 --> 00:03:32.575 The registered dietitian should assess current intake, nausea, eating patterns, nutritional adequacy 00:03:32.874 --> 00:03:36.970 and food access. Pregnancy planning is not a reason to prescribe extreme 00:03:37.056 --> 00:03:40.326 carbohydrate restriction or a universal supplement regimen. 00:03:40.567 --> 00:03:44.407 Coordinate the nutrition plan with glucose monitoring and the medical treatment plan. 00:03:44.706 --> 00:03:49.058 Pregnancy, lactation and weight-loss treatment have different nutritional contexts. 00:03:49.229 --> 00:03:53.073 Here is the decision. Maya uses contraception and is not pregnant. 00:03:53.307 --> 00:03:56.955 She asks which stopping interval applies to her injectable semaglutide. 00:03:57.233 --> 00:04:00.059 Which guidance fits the product and indication in this case? 00:04:00.369 --> 00:04:02.822 Pause here if you would like a moment to think it through. 00:04:03.185 --> 00:04:06.470 The best next step in this case is: Stop Wegovy at least 00:04:06.641 --> 00:04:10.491 two months before the planned pregnancy and coordinate preconception care. 00:04:10.757 --> 00:04:14.640 For this weight-management scenario, the Wegovy instruction is to stop at least 00:04:14.768 --> 00:04:19.376 two months before planned pregnancy. Another product’s contraception precaution is not a 00:04:19.418 --> 00:04:22.650 substitute for this interval. A usable transition note. 00:04:22.980 --> 00:04:27.588 Document the exact product and last dose, the patient’s intended timeline, who 00:04:27.630 --> 00:04:31.001 will make the medication decision and how ongoing glycemic care will be 00:04:31.044 --> 00:04:35.373 provided when diabetes is present. Confirm that the receiving clinician accepts the 00:04:35.416 --> 00:04:41.422 plan. Example scheduling checks are local workflow choices, not universal guideline intervals. 00:04:41.908 --> 00:04:45.961 Here is a practical example: “Medication and reproductive timeline verified. 00:04:46.303 --> 00:04:49.012 Prescribing clinician owns interim glucose care. 00:04:49.247 --> 00:04:54.025 Preconception visit arranged. Patient knows whom to contact if readings, symptoms or 00:04:54.068 --> 00:04:58.127 plans change.” Worked comparison: two plans that sound complete. 00:04:58.575 --> 00:05:03.003 Maya’s first draft says, “Stop the medicine and ask obstetrics about pregnancy.” 00:05:03.212 --> 00:05:07.479 Her revised draft records the product and indication, the last-dose plan, the 00:05:07.522 --> 00:05:11.996 intended conception timeline, and who will answer questions before the obstetric visit. 00:05:12.331 --> 00:05:15.403 The second draft is more usable because another clinician can tell which 00:05:15.531 --> 00:05:17.750 decision has been made and which remains open. 00:05:18.134 --> 00:05:21.249 It does not presume that a referral has transferred responsibility. 00:05:21.547 --> 00:05:23.945 A transition is a sequence of decisions. 00:05:24.252 --> 00:05:29.329 For the diabetes variation, separate three tasks: establish the patient’s current condition; 00:05:29.671 --> 00:05:33.841 agree on a treatment transition; confirm that the follow-up actually occurs. 00:05:34.172 --> 00:05:40.785 Rising glucose requires clinical interpretation alongside symptoms, available readings, current medicines and 00:05:40.828 --> 00:05:45.095 access to care. The vignette does not contain enough information to select 00:05:45.180 --> 00:05:47.576 a dose or prescribe a replacement regimen. 00:05:47.838 --> 00:05:49.545 The treating team must make that decision. 00:05:49.801 --> 00:05:51.678 Close the loop before the patient leaves. 00:05:51.934 --> 00:05:56.030 In this original workflow example, the prescribing office contacts the receiving team 00:05:56.116 --> 00:06:00.398 and identifies an interim clinician. The patient receives a single written next-step 00:06:00.484 --> 00:06:03.876 summary and a contact route if the appointment cannot be obtained. 00:06:04.196 --> 00:06:07.012 The team verifies that the patient can obtain the agreed treatment and 00:06:07.054 --> 00:06:12.327 monitoring supplies. These are practical checks for implementation, not additional learner assignments 00:06:12.498 --> 00:06:16.039 or universal guideline deadlines. Teach-back that tests the plan. 00:06:16.295 --> 00:06:20.117 Instead of asking “Do you understand?”, ask Maya to explain when she 00:06:20.160 --> 00:06:23.061 will contact the prescriber and what she will do if her pregnancy 00:06:23.104 --> 00:06:27.669 plans change. In Priya’s variation, ask whom she will contact about rising 00:06:27.797 --> 00:06:29.453 readings while the referral is pending. 00:06:29.786 --> 00:06:34.010 A correct explanation reveals whether the plan is understandable; an uncertain answer 00:06:34.266 --> 00:06:35.845 is a reason to clarify it. 00:06:36.186 --> 00:06:40.197 Document the agreed plan without making the patient responsible for resolving disagreements 00:06:40.325 --> 00:06:42.650 between offices. Here is the decision. 00:06:42.991 --> 00:06:46.660 In another variation, Priya has type 2 diabetes controlled with a G 00:06:46.660 --> 00:06:51.140 L P 1 receptor agonist. She plans pregnancy and proposes stopping treatment 00:06:51.225 --> 00:06:55.113 until her first prenatal visit. Which plan best addresses this change? 00:06:55.433 --> 00:06:57.523 Pause here if you would like a moment to think it through. 00:06:57.779 --> 00:07:02.473 The best next step in this case is: Coordinate discontinuation, alternative glycemic 00:07:02.601 --> 00:07:07.609 treatment and monitoring before conception. Discontinuation must be paired with active glycemic 00:07:07.737 --> 00:07:12.303 care and a coordinated transition. Triage current symptoms and readings; the treating 00:07:12.388 --> 00:07:14.777 clinician sets the response and review interval. 00:07:14.991 --> 00:07:16.816 Here is what to carry into the next visit. 00:07:17.105 --> 00:07:20.903 Verify exact product indication and intended conception timeline. 00:07:21.244 --> 00:07:24.466 Coordinate product-specific discontinuation with ongoing care. 00:07:24.743 --> 00:07:27.671 Use teach-back and an accepted preconception handoff. 00:07:28.221 --> 00:07:33.212 Now let’s change the situation. Leah is a fictional 32-year-old starting tirzepatide 00:07:33.255 --> 00:07:37.437 for obesity. She uses an oral hormonal contraceptive and does not want 00:07:37.479 --> 00:07:41.740 to become pregnant. She assumes the medication discussion is finished once nausea 00:07:41.826 --> 00:07:43.638 and injection technique have been reviewed. 00:07:43.956 --> 00:07:48.265 The current Zepbound label advises switching to a nonoral contraceptive method or 00:07:48.308 --> 00:07:52.105 adding a barrier method for four weeks after initiation and for four 00:07:52.191 --> 00:07:56.605 weeks after each dose escalation. Discuss the available options without coercion and 00:07:56.648 --> 00:07:59.805 make sure Leah understands that the four-week period can recur when a 00:07:59.848 --> 00:08:03.304 dose is increased. Document the method she chooses and the date it 00:08:03.347 --> 00:08:07.553 begins. At the next planned dose change, revisit the instruction rather than 00:08:07.596 --> 00:08:10.150 assuming the original counseling covers the new interval. 00:08:10.399 --> 00:08:14.495 If she reports missed contraception, a possible pregnancy or concerns about her 00:08:14.538 --> 00:08:19.828 method, arrange timely clinical advice. A medication education handout should not substitute 00:08:19.871 --> 00:08:23.780 for access to that advice. Avoid applying this exact rule to all 00:08:23.908 --> 00:08:27.087 G L P 1 medicines or to every type of contraception. 00:08:27.322 --> 00:08:31.503 Ask the pharmacist to confirm product-specific interactions when the medication list is 00:08:31.588 --> 00:08:36.453 complex. The case tests whether the learner recognizes a specific counseling requirement, 00:08:36.646 --> 00:08:40.059 not whether the patient can memorize a long list of adverse effects. 00:08:40.400 --> 00:08:46.117 Lactation requires a separate discussion. Oral and injectable semaglutide have different considerations. 00:08:46.479 --> 00:08:51.300 Current tirzepatide labeling reports low or undetectable transfer in a single-dose lactation 00:08:51.471 --> 00:08:55.003 study, with no available infant-effect or milk-production data. 00:08:55.292 --> 00:09:00.028 A small pharmacokinetic study does not answer every clinical safety question, particularly 00:09:00.242 --> 00:09:02.474 for a young or medically vulnerable infant. 00:09:02.786 --> 00:09:07.052 The current Wegovy label advises against breastfeeding during treatment with oral tablets 00:09:07.223 --> 00:09:11.617 because its absorption enhancer, S N A C, or its metabolites may 00:09:11.703 --> 00:09:16.391 accumulate in infants. This instruction does not automatically apply to the injection. 00:09:16.882 --> 00:09:21.234 Foundayo is not recommended for nursing women; human milk and infant-effect data 00:09:21.447 --> 00:09:26.597 are unavailable. Review the maternal indication, infant context and alternatives with the 00:09:26.640 --> 00:09:30.246 treating team. A different product changes the instruction. 00:09:30.736 --> 00:09:34.734 Sofia is a fictional 31-year-old starting orforglipron for obesity. 00:09:35.019 --> 00:09:38.582 She uses an oral hormonal contraceptive and does not want pregnancy. 00:09:38.859 --> 00:09:42.605 A copied instruction in her chart says “use backup for four weeks.” 00:09:42.857 --> 00:09:47.208 Sofia’s chart needs a product-specific correction: the Foundayo instruction uses 30 days 00:09:47.294 --> 00:09:51.070 after initiation and each escalation, rather than a rounded four weeks. 00:09:51.348 --> 00:09:53.810 Confirm her chosen method and document the dates. 00:09:54.139 --> 00:09:58.342 An oral medicine is not exempt from reproductive counseling or interaction review. 00:09:58.704 --> 00:10:01.221 Ask what she will do if a dose change or a possible 00:10:01.392 --> 00:10:05.863 pregnancy occurs. Wegovy for the planned weight-management pregnancy case. 00:10:06.195 --> 00:10:10.142 Instruction to verify: Stop at least two months before planned pregnancy. 00:10:10.419 --> 00:10:16.478 Zepbound and oral hormonal contraception. Instruction to verify: Nonoral method or additional 00:10:16.691 --> 00:10:20.025 barrier for four weeks after initiation and each escalation. 00:10:20.330 --> 00:10:24.767 Here is the decision. Consider a separate variation: Leah is taking tirzepatide 00:10:24.895 --> 00:10:29.503 as Zepbound, uses an oral hormonal contraceptive, and does not want pregnancy. 00:10:29.716 --> 00:10:31.581 Her prescriber is increasing the dose. 00:10:31.910 --> 00:10:35.003 She asks whether taking the pill at a different time is enough. 00:10:35.323 --> 00:10:38.417 What counseling is supported by the current Zepbound label? 00:10:38.737 --> 00:10:41.120 Pause here if you would like a moment to think it through. 00:10:41.327 --> 00:10:44.527 The best next step in this case is: Use a non-oral method 00:10:44.740 --> 00:10:48.555 or add a barrier for four weeks after initiation and each escalation. 00:10:48.914 --> 00:10:52.838 Zepbound specifies a nonoral method or added barrier for four weeks after 00:10:53.010 --> 00:10:57.617 initiation and each escalation, including a new increase after earlier precautions were 00:10:57.660 --> 00:11:00.804 completed. Foundayo and oral hormonal contraception. 00:11:01.047 --> 00:11:05.612 Instruction to verify: Nonoral method or additional barrier for 30 days after 00:11:05.783 --> 00:11:10.104 initiation and each escalation. Use dates without confusing the questions. 00:11:10.499 --> 00:11:16.067 A planned-pregnancy stopping interval and a temporary contraception precaution answer different questions. 00:11:16.600 --> 00:11:20.013 In the clinical record, name the question first, then record the product 00:11:20.227 --> 00:11:24.086 and the interval. Let the patient choose among appropriate contraceptive options without 00:11:24.257 --> 00:11:29.163 coercion. If a possible pregnancy or lapse is reported, provide timely individualized 00:11:29.377 --> 00:11:32.159 advice rather than waiting for the next routine titration visit. 00:11:32.467 --> 00:11:36.585 Worked example: the dose-change visit. Leah returns for a dose increase. 00:11:36.947 --> 00:11:40.360 A chart banner says “contraception discussed,” but it does not identify the 00:11:40.403 --> 00:11:43.574 method, product, dose-change date or applicable interval. 00:11:43.843 --> 00:11:47.682 The clinician verifies that she still uses an oral hormonal method, checks 00:11:47.768 --> 00:11:52.376 the current tirzepatide instruction, discusses suitable choices and documents the plan for 00:11:52.419 --> 00:11:56.753 this escalation. The earlier counseling is relevant history; it does not show 00:11:56.839 --> 00:11:58.545 that the new interval has been addressed. 00:11:58.887 --> 00:12:00.930 A calendar is an implementation aid. 00:12:01.503 --> 00:12:05.173 The team places the dose-change date and the relevant precaution interval together 00:12:05.386 --> 00:12:09.226 in the after-visit plan. If the titration date changes, the plan is 00:12:09.269 --> 00:12:13.743 updated. For Sofia, the orforglipron interval is recorded in days rather than 00:12:13.786 --> 00:12:16.341 copied from another product’s week-based instruction. 00:12:16.720 --> 00:12:20.304 This distinction is a label-reading exercise, not a claim that these drugs 00:12:20.347 --> 00:12:22.480 have been compared for contraceptive outcomes. 00:12:22.907 --> 00:12:26.661 The prescriber or pharmacist should resolve uncertainty before the patient relies on 00:12:26.704 --> 00:12:30.498 a copied instruction. Respect preferences and practical barriers. 00:12:30.860 --> 00:12:33.932 Ask what matters to the patient about the available options and whether 00:12:34.018 --> 00:12:36.237 she can obtain and use the selected method. 00:12:36.535 --> 00:12:38.678 Discuss concerns in private when appropriate. 00:12:38.901 --> 00:12:42.357 A person may decline a proposed method; that calls for further shared 00:12:42.443 --> 00:12:46.553 discussion and an individualized plan, not a judgment about adherence. 00:12:46.910 --> 00:12:51.006 The worked example measures the clinician’s counseling decision, not the patient’s willingness 00:12:51.176 --> 00:12:53.566 to accept a particular contraceptive method. 00:12:54.035 --> 00:12:55.927 When the question changes to breastfeeding. 00:12:56.199 --> 00:12:59.889 Build a separate question list: Which exact product and formulation? 00:13:00.209 --> 00:13:03.836 What is the maternal indication? What infant context matters? 00:13:04.049 --> 00:13:08.771 What evidence describes milk transfer, and what evidence describes infant effects? 00:13:09.056 --> 00:13:12.555 Write “not measured” when an outcome is unavailable instead of turning a 00:13:12.597 --> 00:13:15.093 low concentration into a safety conclusion. 00:13:15.541 --> 00:13:18.539 Review current product-specific advice with the treating team. 00:13:18.806 --> 00:13:22.731 This separation helps explain why a pregnancy-planning interval does not answer a 00:13:22.774 --> 00:13:25.099 lactation question. Here is the decision. 00:13:25.419 --> 00:13:29.899 In a separate variation, Sofia starts Foundayo for obesity while using oral 00:13:29.985 --> 00:13:34.714 hormonal contraception. She assumes an oral medicine needs no contraceptive precaution. 00:13:34.991 --> 00:13:37.914 Which instruction matches the July 2026 label? 00:13:38.106 --> 00:13:40.207 Pause here if you would like a moment to think it through. 00:13:40.473 --> 00:13:43.886 The best next step in this case is: Use a non-oral method 00:13:44.142 --> 00:13:48.238 or add a barrier for 30 days after initiation and every escalation. 00:13:48.622 --> 00:13:52.619 Foundayo specifies 30 days after initiation and each escalation. 00:13:52.947 --> 00:13:56.360 Keep that interval distinct from the four-week tirzepatide instruction. 00:13:56.787 --> 00:13:58.963 Here is what to carry into the next visit. 00:13:59.432 --> 00:14:02.376 Confirm the route of contraception and exact medicine. 00:14:02.675 --> 00:14:05.583 Record the chosen method and the start and end dates. 00:14:05.932 --> 00:14:09.473 Revisit the instruction at every relevant escalation. 00:14:10.052 --> 00:14:13.594 For the third case, the follow-up plan becomes especially important. 00:14:13.978 --> 00:14:18.074 Nora is a fictional 34-year-old who reports a positive pregnancy test after 00:14:18.244 --> 00:14:22.164 using semaglutide for weight management. She is frightened and asks whether she 00:14:22.207 --> 00:14:28.138 has harmed the pregnancy. Obtain the exposure dates, formulation, indication, other medicines, 00:14:28.394 --> 00:14:33.778 symptoms and available glycemic history. Arrange prompt obstetric and prescribing-team review. 00:14:34.042 --> 00:14:38.575 Brown and colleagues used claims data to emulate continued versus noncontinued G 00:14:38.575 --> 00:14:41.185 L P 1 dispensing into the first trimester. 00:14:41.543 --> 00:14:45.870 The adjusted risk ratio for nonlive birth was 1.09, with a 95 00:14:45.942 --> 00:14:50.002 percent confidence interval of 0.98 to 1.23. 00:14:50.268 --> 00:14:55.857 Estimates for major congenital malformations and small-for-gestational-age birth were imprecise and compatible 00:14:55.985 --> 00:15:01.135 with clinically important differences. Dispensing is not direct observation of ingestion, and 00:15:01.178 --> 00:15:06.340 residual confounding remains possible. These findings can support a measured conversation after 00:15:06.511 --> 00:15:10.841 an inadvertent exposure. They do not establish intentional use as safe, and 00:15:10.884 --> 00:15:13.785 they do not prove that an individual pregnancy has been injured. 00:15:13.998 --> 00:15:16.846 Avoid a yes-or-no answer the evidence cannot support. 00:15:17.218 --> 00:15:20.034 The next step is a clinical assessment and a plan, not an 00:15:20.077 --> 00:15:24.898 internet verdict. For Nora's weight-management indication, follow the current product instruction to 00:15:24.941 --> 00:15:29.019 discontinue when pregnancy is recognized. Explain how the team will assess her 00:15:29.061 --> 00:15:31.813 health and arrange appropriate prenatal care. 00:15:32.176 --> 00:15:36.454 Offer information about the relevant pregnancy exposure registry through the clinical team. 00:15:36.679 --> 00:15:40.604 An exposure alone is not a basis for an automatic recommendation about 00:15:40.647 --> 00:15:45.801 pregnancy termination. Patient language: "I understand why this worries you. 00:15:46.092 --> 00:15:49.420 The available studies cannot give us a guarantee, but the exposure does 00:15:49.463 --> 00:15:51.809 not by itself tell us that something is wrong. 00:15:52.151 --> 00:15:55.820 Let's review the medicine and timing, follow the current guidance, and arrange 00:15:55.948 --> 00:15:59.337 the care you need." This is an original counseling example for faculty 00:15:59.380 --> 00:16:02.791 review. Use the research without turning it into a guarantee. 00:16:03.088 --> 00:16:07.909 The Brown study is a claims-based target-trial emulation, not a randomized trial 00:16:07.994 --> 00:16:12.858 of planned treatment during pregnancy. The exposure definition, comparison group and outcome 00:16:12.901 --> 00:16:18.812 ascertainment all affect interpretation. A nonsignificant estimate does not demonstrate equivalence. 00:16:19.282 --> 00:16:23.058 The estimate cannot answer whether this particular pregnancy has been affected. 00:16:23.420 --> 00:16:28.224 Respond to the actual encounter. Nora reports using semaglutide for weight management 00:16:28.352 --> 00:16:33.408 and a positive pregnancy test. Confirm the product, formulation, dose and dates, 00:16:33.642 --> 00:16:37.277 but do not delay appropriate care while reconstructing every detail. 00:16:37.670 --> 00:16:41.382 Follow the current label for the indication and arrange prompt obstetric and 00:16:41.424 --> 00:16:46.160 prescribing-team assessment. If diabetes is present, the plan also needs active glucose 00:16:46.246 --> 00:16:51.758 management. Severe or concerning symptoms change urgency and require clinical assessment. 00:16:52.078 --> 00:16:55.620 A practical conversation. “The exposure alone does not tell us what will 00:16:55.662 --> 00:16:59.273 happen. The studies have important limits, so I cannot promise no risk 00:16:59.444 --> 00:17:03.241 or predict harm. We will review the medicine and timing, follow the 00:17:03.284 --> 00:17:06.813 current guidance and arrange the care you need.” Ask what worries Nora 00:17:06.856 --> 00:17:09.458 most and check that she understands the next contact. 00:17:09.842 --> 00:17:12.786 This is an original teaching conversation, not a consent form. 00:17:13.042 --> 00:17:16.608 Here is the decision. Nora has a positive pregnancy test after taking 00:17:16.778 --> 00:17:20.682 semaglutide solely for weight management. Which response best fits? 00:17:20.917 --> 00:17:23.148 Pause here if you would like a moment to think it through. 00:17:23.458 --> 00:17:26.999 The best next step in this case is: Discontinue according to the 00:17:27.042 --> 00:17:31.607 current label and arrange prompt clinical review, without predicting fetal harm from 00:17:31.693 --> 00:17:36.967 exposure alone. Follow the indication-specific instruction and preserve appropriate care. 00:17:37.265 --> 00:17:40.401 Exposure alone does not establish an individual outcome. 00:17:40.721 --> 00:17:46.507 Make the handoff explicit. The obstetric clinician evaluates pregnancy-specific care; the prescribing 00:17:46.678 --> 00:17:51.371 or diabetes team manages the metabolic transition; the registered dietitian supports feasible 00:17:51.499 --> 00:17:55.744 nutritional care. Actual clinical roles must be agreed, not inferred from a 00:17:55.787 --> 00:17:59.008 referral. Document who owns care while appointments are pending. 00:17:59.328 --> 00:18:03.369 The patient should not have to coordinate contradictory medication instructions herself. 00:18:03.867 --> 00:18:05.958 Review nutrition in its current context. 00:18:06.171 --> 00:18:10.842 A restrictive weight-loss plan is not automatically appropriate during pregnancy or lactation. 00:18:11.118 --> 00:18:16.238 Ask about usual intake, nausea, food access and the glucose-monitoring plan, and 00:18:16.281 --> 00:18:18.180 coordinate advice with the treating team. 00:18:18.500 --> 00:18:22.668 Do not provide universal supplement or medication doses from an incomplete vignette. 00:18:22.911 --> 00:18:25.535 Worked appraisal: what the estimate can tell you. 00:18:25.855 --> 00:18:29.652 Consider the reported relative-risk estimate and confidence interval as a range of 00:18:29.738 --> 00:18:32.355 effects compatible with the study’s data and assumptions. 00:18:32.711 --> 00:18:35.207 The result is not a probability assigned to Nora. 00:18:35.442 --> 00:18:39.197 A point estimate close to one can coexist with uncertainty that matters 00:18:39.239 --> 00:18:44.472 clinically. Ask whether the outcome, comparison group and exposure definition match the 00:18:44.514 --> 00:18:48.247 question the patient is asking before translating a study into counseling. 00:18:48.567 --> 00:18:50.732 Separate three statements in the conversation. 00:18:51.061 --> 00:18:55.712 First, explain what is known about the reported exposure: the product, reason 00:18:55.840 --> 00:19:00.448 for use and available dates. Second, explain what remains uncertain about pregnancy 00:19:00.576 --> 00:19:04.082 outcomes. Third, state the action that will happen now. 00:19:04.344 --> 00:19:08.014 Keeping these statements separate avoids using a reassuring tone as a substitute 00:19:08.056 --> 00:19:11.640 for a care plan. It also prevents the product instruction to discontinue 00:19:11.811 --> 00:19:15.255 from being heard as proof that an individual pregnancy has been harmed. 00:19:15.541 --> 00:19:20.661 An original handoff example. “Nora reports a positive pregnancy test after weight-management 00:19:20.747 --> 00:19:25.867 semaglutide exposure. The prescribing clinician is reviewing the product-specific instruction and current 00:19:25.952 --> 00:19:30.450 health needs. Obstetric review has been requested, with the receiving team and 00:19:30.493 --> 00:19:34.162 contact route documented. The patient has been told how to reach us 00:19:34.247 --> 00:19:38.118 if she cannot obtain the visit.” Complete the actual exposure details and 00:19:38.161 --> 00:19:40.273 clinical plan in the patient’s medical record. 00:19:40.593 --> 00:19:44.220 This example is a communication structure, not a universal treatment order. 00:19:44.518 --> 00:19:46.365 Judge the quality of the completed visit. 00:19:46.675 --> 00:19:50.601 A useful encounter ends with an answer to four practical questions: What 00:19:50.643 --> 00:19:53.694 changes today? Who owns the next clinical decision? 00:19:54.014 --> 00:19:55.699 How will the patient reach that person? 00:19:56.062 --> 00:19:58.740 How will the originating office learn that follow-up occurred? 00:19:59.030 --> 00:20:02.016 These questions remain relevant even when the research is incomplete. 00:20:02.400 --> 00:20:05.195 Apply that reasoning to the next clinical conversation. 00:20:05.728 --> 00:20:09.985 Here is the decision. Which statement best communicates the early-exposure evidence? 00:20:10.358 --> 00:20:12.684 Pause here if you would like a moment to think it through. 00:20:13.089 --> 00:20:16.460 The best next step in this case is: The available data cannot 00:20:16.716 --> 00:20:21.068 predict an individual outcome; explain the uncertainty and the agreed next clinical 00:20:21.196 --> 00:20:26.593 step. Distinguish observational association, uncertainty and individual prediction. 00:20:26.934 --> 00:20:31.478 A clear action plan supports counseling without unsupported reassurance or alarm. 00:20:31.798 --> 00:20:33.663 Here is what to carry into the next visit. 00:20:33.991 --> 00:20:36.210 Review exposure and current maternal health. 00:20:36.423 --> 00:20:39.772 Follow the product-specific instruction and preserve necessary care. 00:20:40.050 --> 00:20:43.407 Explain uncertainty and confirm the accepting clinical team. 00:20:43.978 --> 00:20:47.562 Before you go, bring the three cases back to one question: what 00:20:47.605 --> 00:20:49.312 will you do differently at the next visit? 00:20:49.610 --> 00:20:51.530 Name the exact product and indication. 00:20:51.829 --> 00:20:54.876 Separate pregnancy planning from contraception and lactation. 00:20:55.150 --> 00:20:58.051 Then coordinate the care that continues through the change. 00:20:58.520 --> 00:21:02.929 You’ll find the source references, transcript and clinical resources beside this episode. 00:21:03.328 --> 00:21:06.784 To record your answers and complete the learning activity, return to the 00:21:06.827 --> 00:21:09.707 activity page for the questions and brief evaluation. 00:21:10.155 --> 00:21:12.480 This has been HEART RESERVE Clinical Conversations. 00:21:12.757 --> 00:21:15.348 I’m Lisa Zahakos. Thank you for listening.